Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
Rocket Pharmaceuticals (NASDAQ: RCKT), a late-stage biotechnology company focused on genetic therapies for rare disorders, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's CEO, Gaurav Shah, M.D., will engage in a fireside chat scheduled for 8:45 a.m. ET on Tuesday, April 8, 2025. The presentation will be accessible via webcast on the company's Investors section website, with replay availability for approximately 30 days after the event.
Rocket Pharmaceuticals (NASDAQ: RCKT), un'azienda biotecnologica in fase avanzata focalizzata su terapie genetiche per malattie rare, ha annunciato la sua partecipazione alla 24a Conferenza Virtuale Annuale di Needham sulla Salute.
Il CEO dell'azienda, Gaurav Shah, M.D., parteciperà a una chiacchierata informale programmata per 8:45 a.m. ET di martedì 8 aprile 2025. La presentazione sarà accessibile tramite webcast nella sezione Investitori del sito web dell'azienda, con disponibilità di replay per circa 30 giorni dopo l'evento.
Rocket Pharmaceuticals (NASDAQ: RCKT), una empresa biotecnológica en etapa avanzada centrada en terapias génicas para trastornos raros, ha anunciado su participación en la 24ª Conferencia Virtual Anual de Salud de Needham.
El CEO de la empresa, Gaurav Shah, M.D., participará en una charla informal programada para 8:45 a.m. ET del martes 8 de abril de 2025. La presentación estará disponible a través de un webcast en la sección de Inversores del sitio web de la empresa, con disponibilidad de repetición durante aproximadamente 30 días después del evento.
로켓 제약 (NASDAQ: RCKT), 희귀 질환을 위한 유전자 치료에 집중하는 후기 단계 생명공학 회사가 제24회 니드햄 가상 의료 회의에 참여한다고 발표했습니다.
회사의 CEO인 가우라브 샤, M.D.는 2025년 4월 8일 화요일 오전 8시 45분 ET에 예정된 대화에 참여할 것입니다. 발표는 회사의 투자자 섹션 웹사이트를 통해 웹캐스트로 접근할 수 있으며, 이벤트 후 약 30일 동안 재생할 수 있습니다.
Rocket Pharmaceuticals (NASDAQ: RCKT), une entreprise biopharmaceutique en phase avancée axée sur les thérapies géniques pour les troubles rares, a annoncé sa participation à la 24e Conférence Virtuelle Annuelle de Needham sur la Santé.
Le PDG de l'entreprise, Gaurav Shah, M.D., participera à une discussion informelle prévue pour 8h45 ET le mardi 8 avril 2025. La présentation sera accessible via un webcast dans la section Investisseurs du site web de l'entreprise, avec une rediffusion disponible pendant environ 30 jours après l'événement.
Rocket Pharmaceuticals (NASDAQ: RCKT), ein biopharmazeutisches Unternehmen in der späten Entwicklungsphase, das sich auf Gentherapien für seltene Erkrankungen konzentriert, hat seine Teilnahme an der 24. jährlichen virtuellen Gesundheitskonferenz von Needham bekannt gegeben.
Der CEO des Unternehmens, Gaurav Shah, M.D., wird an einem informellen Gespräch teilnehmen, das für 8:45 a.m. ET am Dienstag, den 8. April 2025 angesetzt ist. Die Präsentation wird über ein Webcast im Investorenbereich der Unternehmenswebsite zugänglich sein, mit einer Wiederholung, die etwa 30 Tage nach der Veranstaltung verfügbar sein wird.
- None.
- None.
A webcast of the fireside chat will be available here and on the Investors section of the Company’s website. An archived replay of the webcast will be available for approximately 30 days following the event.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Rocket’s innovative multi-platform approach allows us to design the optimal gene therapy for each indication, creating potentially transformative options that enable people living with devastating rare diseases to experience long and full lives.
Rocket’s adeno-associated viral (AAV) vector-based cardiovascular portfolio includes a late-stage program for Danon Disease, a devastating heart failure condition resulting in thickening of the heart, an early-stage program in clinical trials for PKP2-arrhythmogenic cardiomyopathy (ACM), a life-threatening heart failure disease causing ventricular arrhythmias and sudden cardiac death, and a pre-clinical program targeting BAG3-associated dilated cardiomyopathy (DCM), a heart failure condition that causes enlarged ventricles.
Rocket’s lentiviral (LV) vector-based hematology portfolio consists of late-stage programs for Fanconi Anemia (FA), a difficult-to-treat genetic disease that leads to bone marrow failure (BMF) and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia.
For more information about Rocket, please visit www.rocketpharma.com and follow us on LinkedIn, YouTube, and X.
Rocket Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements concerning Rocket’s future expectations, plans and prospects that involve risks and uncertainties, as well as assumptions that, if they do not materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this release are forward-looking statements. You should not place reliance on these forward-looking statements, which often include words such as “could,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “will give,” “estimate,” “seek,” “will,” “may,” “suggest” or similar terms, variations of such terms or the negative of those terms. These forward-looking statements include, but are not limited to, statements concerning Rocket’s expectations regarding the safety and effectiveness of product candidates that Rocket is developing to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Danon Disease (DD) and other diseases, the expected timing and data readouts of Rocket’s ongoing and planned clinical trials, the expected timing and outcome of Rocket’s regulatory interactions and planned submissions, including the timing and outcome of the FDA’s review of the additional CMC information that Rocket will provide in response to the FDA’s request, the safety, effectiveness and timing of pre-clinical studies and clinical trials, Rocket’s ability to establish key collaborations and vendor relationships for its product candidates, Rocket’s ability to develop sales and marketing capabilities or enter into agreements with third parties to sell and market its product candidates, Rocket’s ability to expand its pipeline to target additional indications that are compatible with its gene therapy technologies, Rocket’s ability to transition to a commercial stage pharmaceutical company, and Rocket’s expectation that its cash, cash equivalents and investments will be sufficient to funds its operations into the third quarter of 2026. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket’s dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, unexpected expenditures, Rocket’s competitors’ activities, including decisions as to the timing of competing product launches, pricing and discounting, Rocket’s ability to develop, acquire and advance product candidates into, enroll a sufficient number of patients into, and successfully complete, clinical studies, the integration of new executive team members and the effectiveness of the newly configured corporate leadership team, Rocket’s ability to acquire additional businesses, form strategic alliances or create joint ventures and its ability to realize the benefit of such acquisitions, alliances or joint ventures, Rocket’s ability to obtain and enforce patents to protect its product candidates, and its ability to successfully defend against unforeseen third-party infringement claims, as well as those risks more fully discussed in the section entitled “Risk Factors” in Rocket’s Annual Report on Form 10-K for the year ended December 31, 2024, filed February 27, 2025 with the SEC and subsequent filings with the SEC including our Quarterly Reports on Form 10-Q. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250403197854/en/
Media & Investors
Meg Dodge
mdodge@rocketpharma.com
Media
Kevin Giordano
media@rocketpharma.com
Source: Rocket Pharmaceuticals, Inc.
FAQ
When is Rocket Pharmaceuticals (RCKT) presenting at the Needham Healthcare Conference 2025?
How can investors watch RCKT's Needham Conference presentation?
What type of therapies does Rocket Pharmaceuticals (RCKT) focus on?
Who will represent RCKT at the 2025 Needham Healthcare Conference?
